glp 1 hypothalamus Glucagon‐like peptide‐1 (GLP‐1) signalling in the brain: From neural circuits and metabolism to therapeutics - Kabahizi - 2022 - British Journal of Pharmacology GLP-1 in addiction medicine: GLP-1

Many patients observe changes occurring in a few weeks

Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems

Particularly noteworthy is that in patients with both type 2 diabetes and MASLD, after 24 weeks of treatment with a 10 mg dose of efinopegdutide, liver fat content reduced by 72.7%, a result that is superior to the 42.3% reduction achieved with a 1 mg dose of semaglutide, despite a similar overall weight loss being observed with the two interventions

Regulated cell death pathways and their roles in homeostasis, infection, inflammation, and tumorigenesis

The half-life is the amount of time it takes for half of the medication to be cleared from your system, or more simply, how long the drug continues to work after you take it